- Home
- VVV vs ACAD Comparison
VVV vs ACAD Comparison
Compare VVV & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVV
- ACAD
- Stock Information
- Founded
- VVV 1866
- ACAD 1993
- Country
- VVV United States
- ACAD United States
- Employees
- VVV N/A
- ACAD N/A
- Industry
- VVV Major Chemicals
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- VVV Industrials
- ACAD Health Care
- Exchange
- VVV Nasdaq
- ACAD Nasdaq
- Market Cap
- VVV 5.0B
- ACAD 4.3B
- IPO Year
- VVV 2016
- ACAD 2004
- Fundamental
- Price
- VVV $40.17
- ACAD $24.67
- Analyst Decision
- VVV Buy
- ACAD Buy
- Analyst Count
- VVV 12
- ACAD 21
- Target Price
- VVV $43.00
- ACAD $29.30
- AVG Volume (30 Days)
- VVV 1.4M
- ACAD 1.8M
- Earning Date
- VVV 08-06-2025
- ACAD 11-05-2025
- Dividend Yield
- VVV N/A
- ACAD N/A
- EPS Growth
- VVV 68.45
- ACAD 615.00
- EPS
- VVV 2.14
- ACAD 1.33
- Revenue
- VVV $1,692,000,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- VVV $6.86
- ACAD $14.01
- Revenue Next Year
- VVV $14.28
- ACAD $11.72
- P/E Ratio
- VVV $18.75
- ACAD $18.55
- Revenue Growth
- VVV 7.53
- ACAD 14.41
- 52 Week Low
- VVV $31.02
- ACAD $13.40
- 52 Week High
- VVV $43.74
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- VVV 59.56
- ACAD 49.69
- Support Level
- VVV $38.95
- ACAD $23.34
- Resistance Level
- VVV $40.68
- ACAD $25.90
- Average True Range (ATR)
- VVV 0.74
- ACAD 0.78
- MACD
- VVV 0.06
- ACAD -0.28
- Stochastic Oscillator
- VVV 80.26
- ACAD 40.18
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.